Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374540 · ClinicalTrials.gov registry record
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
A clinical trial of Nonvalvular Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 78,517
- Enrollment target
- 1
- Study location
NCT03374540 is a study of Nonvalvular Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 78,517 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03374540, a study of Nonvalvular Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 78,517 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice. The primary objective in this study was to evaluate the combined end point of stroke or systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs. VKA.
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Vitamin K antagonist (VKA)
Study Locations (1)
Washington
- Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78,517 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374540
The ClinicalTrials.gov registry entry for NCT03374540 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 78,517 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03374540 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03374540 about?
NCT03374540 is a clinical study titled "Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients". The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice. The pri...
What is the current status of trial NCT03374540?
This trial is currently completed. The enrollment target is 78,517 participants. The study started on 2017-12-01. Estimated completion is 2019-08-30.
What conditions does trial NCT03374540 study?
This clinical trial studies the following conditions: Nonvalvular Atrial Fibrillation.
What interventions are being tested in trial NCT03374540?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Vitamin K antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT03374540?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03374540 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonvalvular Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.